LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "axicabtagene ciloleucel" as a keyword



Predictors and management of relapse to axicabtagene ciloleucel in patients with aggressive B-cell lymphoma.

Sign Up to like & get
recommendations! Published in 2021 at "Hematology/oncology and stem cell therapy"

DOI: 10.1016/j.hemonc.2021.09.001

Abstract: OBJECTIVE/BACKGROUND Despite the success of chimeric antigen receptor (CAR) T-cell therapy in patients with aggressive non-Hodgkin lymphoma (aNHL), some patients still fail treatment, and their prognosis is dismal. METHODS We performed a retrospective study of… read more here.

Keywords: axicabtagene ciloleucel; patients aggressive; axi cel; therapy ... See more keywords

Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma

Sign Up to like & get
recommendations! Published in 2022 at "Expert Review of Anticancer Therapy"

DOI: 10.1080/14737140.2022.2096009

Abstract: ABSTRACT Introduction Axicabtagene ciloleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy that was recently approved for relapsed or refractory follicular lymphoma following progression on two or more lines of therapy including an… read more here.

Keywords: axicabtagene; relapsed refractory; follicular lymphoma; axicabtagene ciloleucel ... See more keywords

Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma

Sign Up to like & get
recommendations! Published in 2023 at "Expert Opinion on Drug Safety"

DOI: 10.1080/14740338.2023.2177268

Abstract: ABSTRACT Introduction CD19-directed chimeric antigen receptor (CAR) T-cell therapy is a highly effective therapy for patients with relapsed/refractory large B-cell lymphoma (LBCL) and three CD19 CAR T-cell products (axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel) are… read more here.

Keywords: cell; safety; therapy; axicabtagene ciloleucel ... See more keywords

Cost-utility analysis of second-line axicabtagene ciloleucel versus standard of care in Japan based on the ZUMA-7 trial

Sign Up to like & get
recommendations! Published in 2024 at "Future Oncology"

DOI: 10.1080/14796694.2024.2351353

Abstract: Aim: To perform a cost–effectiveness analysis comparing axicabtagene ciloleucel (axi-cel) with standard of care (SoC; salvage chemoimmunotherapy, followed by high-dose therapy with autologous stem cell rescue for responders) for second-line (2L) treatment of adults with… read more here.

Keywords: standard care; zuma trial; axicabtagene ciloleucel; cost ... See more keywords

Impact of hypoalbuminemia on the prognosis of relapsed/refractory B‐cell lymphoma treated with axicabtagene ciloleucel

Sign Up to like & get
recommendations! Published in 2021 at "European Journal of Haematology"

DOI: 10.1111/ejh.13609

Abstract: Hypoalbuminemia is a known adverse prognostic factor in lymphomas. Yet, it is unknown if axicabtagene ciloleucel (axi‐cel) overcomes the adverse prognostic impact of hypoalbuminemia in relapsed/refractory large B‐cell lymphoma. read more here.

Keywords: axicabtagene ciloleucel; relapsed refractory; impact hypoalbuminemia; hypoalbuminemia ... See more keywords

Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma

Sign Up to like & get
recommendations! Published in 2024 at "Journal for Immunotherapy of Cancer"

DOI: 10.1136/jitc-2024-008975

Abstract: Background Fludarabine in combination with cyclophosphamide (FC) is the standard lymphodepletion regimen for CAR T-cell therapy (CAR T). A national fludarabine shortage in 2022 necessitated the exploration of alternative regimens with many centers employing single-agent… read more here.

Keywords: lymphodepletion; cell lymphoma; bendamustine; axicabtagene ciloleucel ... See more keywords

Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas

Sign Up to like & get
recommendations! Published in 2020 at "Therapeutic Advances in Hematology"

DOI: 10.1177/2040620720902899

Abstract: Aggressive large B-cell lymphomas represent a diverse population of diseases that are typically treated with anti-CD20 based immunochemotherapy. While this treatment is effective for a large proportion of patients, those that become refractory to induction… read more here.

Keywords: axicabtagene ciloleucel; cell lymphomas; treatment; large cell ... See more keywords

A real-world experience of axicabtagene ciloleucel CAR-T in refractory/relapsed B-cell lymphoma from a tertiary center in Saudi Arabia

Sign Up to like & get
recommendations! Published in 2025 at "Blood"

DOI: 10.1182/blood-2025-7236

Abstract: Introduction: Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 CAR T-cell therapy approved for the treatment of relapsed or refractory large B-cell lymphoma (LBCL) who have received a prior two or more lines of therapy. Our… read more here.

Keywords: cell lymphoma; car; cell; axicabtagene ciloleucel ... See more keywords

5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1).

Sign Up to like & get
recommendations! Published in 2023 at "Blood"

DOI: 10.1182/blood.2022018893

Abstract: In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrated durable responses at 2 years in patients with refractory large B-cell lymphoma (LBCL).… read more here.

Keywords: cell; year; lymphoma; cell lymphoma ... See more keywords
Photo from wikipedia

Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.

Sign Up to like & get
recommendations! Published in 2020 at "Blood advances"

DOI: 10.1182/bloodadvances.2020001837

Abstract: The impact of bridging therapy (BT) administered between leukapheresis and chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is unclear. We evaluated the influence of BT (systemic therapy [ST], radiation therapy [RT],… read more here.

Keywords: axicabtagene ciloleucel; large cell; therapy; bridging therapy ... See more keywords

Circulating Tumor DNA Adds Specificity to PET following Axicabtagene Ciloleucel in Large B-cell Lymphoma.

Sign Up to like & get
recommendations! Published in 2023 at "Blood advances"

DOI: 10.1182/bloodadvances.2022009426

Abstract: We examined the meaning of metabolically active lesions on 1 month restaging nuclear imaging of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) receiving axicabtagene ciloleucel (axi-cel) by assessing the relationship between total metabolic tumor… read more here.

Keywords: cell; cell lymphoma; month; large cell ... See more keywords